Immunology

Gould Fellowship in Cancer Immunology job with UNIVERSITY OF SOUTHAMPTON | 304380 – Times Higher Education

Cancer Sciences

Location: Southampton General HospitalSalary: 40,931 to 51,805Full Time Fixed TermClosing Date: Tuesday 06 September 2022Interview Date: To be confirmedReference: 1933522CM

An exciting opportunity presents itself for a new research fellowship to be established in the Centre for Cancer Immunology, within the School of Cancer Sciences at the Southampton General Hospital site. The centre, opened in 2018, builds on a 40-year history of pioneering immunology and cancer research at Southampton, and represents the first dedicated cancer immunology centre in the UK. The activities in the centre span from pioneering discovery science to applied research and pre-clinical modelling and, crucially, onto first-in-human clinical trials and beyond. The centre houses world-class research facilities, including state-of-the-art scientific laboratories and a clinical trials unit all within the same building to facilitate the most efficient translation of our findings into improved treatments for Cancer patients.

This position is associated with significant resources, up to 150k/year, to enable the appointee to develop an independent research programme. The position is expected to lead to success of the appointee in obtaining extramural funding on the pathway to independence. The appointee will be highly motivated and excited by the challenges involved in working collaboratively with the existing research groups in the centre, whilst building their own identifiable research themes. Current research programmes involve antibody engineering, immunotherapy, immune receptor biology and antigen presentation related to the treatment of cancer (www.southampton.ac.uk/youreit/meet-the-team). Ongoing activities also include mechanistic studies of therapies for autoimmunity. Research in the centre is highly interdisciplinary, and include bioinformatics, advanced microscopy and close interactions with clinicians as well as a wide group of collaborating scientists across the University (www.southampton.ac.uk/youreit/cancer-scientists)

The appointee is expected to have an outstanding research background, including high quality publications, in any area related to cancer immunology. Typically, it is expected that the appointee will have successfully completed several years of post-doctoral research, but outstanding candidates with less experience will also be considered.

The post-holder will possess relevant academic qualifications and work experience, in addition to good IT skills. Non-UK citizens are also encouraged to apply.

The position is initially fully funded for two years. Availability of funds for a third year will be dependent on satisfactory progress.

Informal queries can directed to: Professor Sally Ward (E.S.Ward@soton.ac.uk)

You should submit your completed online application form at https://jobs.soton.ac.uk. The application deadline will be midnight on the closing date sated above. If you need any assistance, please call Jane Sturgeon (Recruitment Team) on +44 (0) 23 8059 2750 or email recruitment@soton.ac.uk. Please quote reference 1933522CM on all correspondence.

Continued here:
Gould Fellowship in Cancer Immunology job with UNIVERSITY OF SOUTHAMPTON | 304380 - Times Higher Education

Immunology

Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships and Technology Awards – PR Web

Society for Immunotherapy of Cancer (SITC)

MILWAUKEE (PRWEB) August 12, 2022

The Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the recipients of the 2022 Fellowships and Technology Awards, which support the next generation of cancer immunotherapy and tumor immunology experts through dedicated funding of novel research.

Together with the immense generosity of our supporters, SITC is honored to help young investigators realize their cancer immunotherapy research dreams, said SITC President Patrick Hwu, MD. It is our hope that these young researchers turn their dreams and cure into a reality for all cancer patients.

These awards are financially supported through the Forward Fund, which was established by SITC in 2012 to stimulate the future of science, development and application of cancer immunology and immunotherapy through financially supporting its education and research. Since 2014, SITC has awarded more than $5 million in funding to deserving early career scientists in the field of cancer immunotherapy.

The 2022 SITC Fellowship and Technology Award recipients are:

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational FellowshipAward Amount: $200,000 (two-year)Awardee: Simone Minnie, PhDInstitution: Fred Hutchinson Cancer Research Center Project Title: Harnessing Treg fragility to improve anti-myeloma immune responses

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies FellowshipAward Amount: $100,000 (one-year)Awardee: John Ligon, MDInstitution: University of FloridaProject Title: Leveraging CD70 CXCR2-modified CAR T-cells for treating AML

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical FellowshipAward Amount: $100,000 (one-year)Awardee: Jonathan Chen, MD, PhDInstitution: Massachusetts General HospitalProject Title: Dissecting the tumor immunity multicellular network

SITC-Merck Cancer Immunotherapy Clinical FellowshipAward Amount: $100,000 (one-year)Awardee: Hitomi Hosoya, MD, PhDInstitution: Stanford UniversityProject Title: Cell-free DNA-based Platform to Determine Treatment Response and Resistant Mechanisms to CAR T-cell Therapy in Multiple Myeloma

SITC-Genentech Women in Cancer Immunotherapy FellowshipAward Amount: $50,000 (one-year)Awardee: Shu-chin Lai, PhDInstitution: Huntsman Cancer Institute, University of UtahProject Title: Augmenting T cell immunity to facilitate metastatic breast cancer treatment

SITC-Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy FellowshipAward Amount: $50,000 (one-year)Awardee: Mara De Martino, PhDInstitution: Weill Cornell MedicineProject Title: Targeting FASN to sensitize irradiated glioblastoma to immunotherapy

SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical FellowshipAward Amount: $40,000 (one-year)Awardee: Steven Blum, MDInstitution: Dana-Farber Cancer Institute, Massachusetts General HospitalProject Title: Distinguishing Immune-Related Adverse Events (irAEs) from Anti-Tumor Immunity

SITC-Natera ctDNA in Immunotherapy Response Monitoring Fellowship and Technology AwardAward: $40,000 and access to Nateras Signatera testing technology Awardee: Mariya Rozenblit, MDInstitution: Yale UniversityProject Title: The tumor microenvironment of triple negative breast cancers with detectable circulating tumor DNA after pembrolizumab treatment

SITC-NanoString Technologies Single Cell Biology AwardAward: Access to NanoString Technologies CosMx Spatial Molecular Imager (SMI)Awardee: Elshad Hasanov, MD, PhDInstitution: University of Texas MD Anderson Cancer CenterProject Title: CosMxing renal cell carcinoma brain metastases to decipher immune checkpoint inhibitor resistance mechanisms at single-cell and spatial context

This years SITC Forward Fund Fellowships and Technology Awards were made possible through the generosity of Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, Mallinckrodt Pharmaceuticals, Merck, Nektar Therapeutics, NanoString Technologies and Natera Technologies. The fellowship and technology award recipients will be honored during a ceremony at the societys 37th Annual Meeting at the Boston Convention and Exhibition Center in Boston, Massachusetts.

To learn more about current and past SITC Fellowship and Technology Award recipients, visit SITCs website.

About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word cure a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Share article on social media or email:

View original post here:
Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships and Technology Awards - PR Web

Immunology

Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities – Yahoo Finance

Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development

TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development.

Chemomab logo (PRNewsfoto/Chemomab Therapeutics, Ltd.)

"Chemomab is distinguished by the strength of its science, and we are fortunate these two premiere scientific and medical professionals are assuming critical roles as we progress the development of CM-101, our pipeline in a product with breakthrough potential," said Dale Pfost, PhD, Chief Executive Officer of Chemomab. "We are preparing to report topline results from our Phase 2 trial in liver fibrosis patients later this year, we are expanding our Phase 2 trial of CM-101 in primary sclerosing cholangitis, we will soon be launching a Phase 2 biological proof of concept trial in systemic sclerosis, and we are assessing potential new indications for CM-101 in other fibro-inflammatory disorders. Dr. Vaknin's more than 20 years of broad-ranging experience in immunology, bioassay development, and antibody R&D and manufacturing will be invaluable as we work to accelerate advancement of our pipeline programs."

Dr. Vaknin brings Chemomab more than two decades of biotechnology drug discovery and development experience in immunology, antibody development, translational research and bioassay development, including more than a decade in senior science roles at Compugen, Ltd. He most recently served as Director of Preclinical Bioassays, where he oversaw preclinical bioassay development and related activities, while working with computational and validation teams to support discovery of novel drug targets and biomarkers. Prior to Compugen, Dr. Vaknin served as Chief Technology Officer at Active P, where he led the development of orally available therapeutic peptides. Earlier in his career, he served as External Scientific Consultant for the Department of Neurobiology at Israel's Weizmann Institute of Science. Dr. Vaknin holds a PhD in immunology and a BA in life sciences from The Hebrew University of Jerusalem, where he also received an MBA in finance.

Story continues

Dr. Pfost continued, "Dr. Crater's extensive background in medical affairs and clinical trial design and execution across a broad range of therapeutic indications will be instrumental as we ramp up our clinical activities. She has highly relevant experience leading clinical research programs in immuno-inflammation and orphan diseases. Her decade as a front-line physician gives her a first-hand appreciation for the essential roles of patients and physicians in the successful development of new therapies. I am delighted to welcome Ilan and Chris to the Chemomab senior team at this exciting time in our evolution."

Dr. Crater has served as a medical monitor, safety physician, therapeutic expert and study director in all phases of clinical development, including extensive experience in data quality and safety monitoring. Her career spans working in-house at pharmaceutical and biotechnology firms, as well as at major clinical research organizations (CROs). Previously Dr. Crater served as Senior Clinical Trial Physician at Bristol-Myers Squibb, where she was responsible for the review and interpretation of clinical data while contributing to strategic decisions on clinical study design and asset advancement. Dr. Crater also served in senior clinical development roles with PRA Health Sciences and PAREXEL International. Earlier in her career, Dr. Crater worked as an internal medicine physician. She received an MD degree from the University of Tennessee and holds a BS from Rhodes College. Dr. Crater is board certified in Internal Medicine.

About Chemomab Therapeutics

Chemomabis a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022. For more information, visitchemomab.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab's current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including: risks related to Chemomab's ability to effectively implement the revised clinical strategy and its ability to achieve the anticipated results; risks related to the projections and associated benefits in pursuing the contemplated changes to the clinical strategy; risks associated with the ongoing transitions of certain of our executive officers; the uncertain and time-consuming regulatory approval process; risks related to Chemomab's ability to correctly manage its operating expenses and its expenses; Chemomab's plans to develop and commercialize its product candidates, focusing on CM-101; the timing of initiation of Chemomab's planned clinical trials; the timing of the availability of data from Chemomab's clinical trials including any potential delays associated with Chemomab's contemplated revised clinical strategy; the timing of any planned investigational new drug application or new drug application; Chemomab's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Chemomab's product candidates; Chemomab's commercialization, marketing and manufacturing capabilities and strategy; Chemomab's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. Additional risks and uncertainties relating to Chemomab's and its business can be found under the caption "Risk Factors" and elsewhere in Chemomab's filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except to the extent required by applicable law.

Contacts:

Media:

Investor Relations:

Barbara Lindheim

Irina Koffler

Chemomab Therapeutics

LifeSci Advisors, LLC

Consulting Vice President

Phone: +1-917-734-7387

Investor & Public Relations,

ir@chemomab.com

Strategic Communications

Phone: +1-917-355-9234

barbara@chemomab.com

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-adds-highly-experienced-executives-further-strengthening-its-rd-and-clinical-capabilities-301604869.html

SOURCE Chemomab Therapeutics, Ltd.

See original here:
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities - Yahoo Finance

Immunology

Serum Calprotectin Levels Linked to Subclinical Carotid Atherosclerosis in Patients With Psoriatic Arthritis – Rheumatology Network

In patients with psoriatic arthritis (PsA), serum calprotectin levels are associated with the presence of carotid plaques, according to a study published in Frontiers in Immunology.1

In PsA patients, serum calprotectin level was independently associated with the presence of carotid plaques, probably involving platelet and endothelial cells activation, Isaac Cheng, PhD, of The Chinese University of Hong Kong in Shatin, China, and colleagues, wrote. Moreover, subclinical carotid atherosclerosis was associated with the inflammatory burden (as reflected by the disease duration) in these patients.

While the association between PsA and increased cardiovascular (CV) disease risk is well established, only limited data is available on the underlying mechanisms.

This cross-sectional study included 78patients (52.6% male, mean age 52 years) with PsA but without CV disease. Calprotectin levels in serum were quantified and high-resolution ultrasound was used to determine carotid intima-media thickness and the presence of plaque.

Of the patients, 37.2% had carotid plaques. Serum calprotectin level was significantly higher in the group with carotid plaques compared with those without carotid plaques (721.3 ng/ml vs 564.6 ng/ml, P = 0.005). Serum calprotectin level correlated with PsA disease duration and mean carotid intima-media thickness.

Least absolute shrinkage and selection operator regression was performed to screen out 19 predictive variables including age, gender, traditional CV risk factors, medication use, clinical features and disease activity. Ln-calprotectin (OR: 3.38, 95% CI [1.37, 9.47]; P = 0.026) and PsA disease duration (1.09, 95% CI [1.01, 1.18]; P = 0.013) were statistically significant in predicting carotid plaque.

Investigators developed a nomogram for discriminating the presence of carotid plaque, which they said was an easy reference for clinical practice, with good accuracy, sensitivity and specificity (AUC 0.744, sensitivity 65%, specificity 79%). They concluded that serum calprotectin level may be a useful biomarker associated with a high inflammatory burden and the presence of subclinical carotid atherosclerosis in patients with PsA.

A limitation of the study was that most of the patients had low disease activity, thus the results may not be applicable to patients with moderate or high disease activity.

Reference:

Cheng IT, Meng H, Li M, et al. Serum Calprotectin Level Is Independently Associated With Carotid Plaque Presence in Patients With Psoriatic Arthritis.Front Med (Lausanne). 2022;9:932696. Published 2022 Jul 8. doi:10.3389/fmed.2022.932696

See the rest here:
Serum Calprotectin Levels Linked to Subclinical Carotid Atherosclerosis in Patients With Psoriatic Arthritis - Rheumatology Network

Immunology

Professor Dr.Tzenios was inducted into the hall of Fame of the Medical Research Council (FMRC) USA by honoring him with a distinguished FMRC…

Professor Dr. Nikolaos Tzenios,Ph.D., FRSPH, FRSM, FAAMFM, FWAMS, FMRC, AcIASS, mRSB, DABAAHP|, a University Professor of Public Health,had been inducted into the hall of fame by honoring him with theFellowship of theMedical Research Council (FMRC) for hisremarkable contribution to medical research. His international journal publications have received international acclaim and significantly impacted the global research community.

This is to certify that renowned researcher Professor Dr.Nikolaos Tzenios is hereby recognized and honored as aFellow of Medical Research Council (FMRC).The designated fellow is elected to the esteemed grade for theexceptional achievements in pursuit of advanced studies &research in his work and remarkable contributions to CancerResearch.Dr. Vivek Dubey, (MS, Ph.D., University of Wisconsin)Secretary Open Association of Research Society, Delaware.

Professor Dr. Nikolaos Tzenios research articles with several citations show his profound understanding of research methodology and display his keen insight into the subtle aspects of his field. They were selected for publication after passing through the exhaustive peer-review parameters and approved by an editorial board comprising eminent researchers and scientists.

Dr. Nikolaos Tzenios shows the originality of thought and delves into hitherto untouched areas.

TheFellowship of theMedical Research CouncilIt is not only an award but also a membership granted to individuals which the Open Association of Research Society Judges feel that the Scientist has made a substantial contribution to the improvement of Cancer Research.

The designated Fellows are the most eminent scientists, engineers, and technologists worldwide. The credentials of Fellow designation signify that the researcher has gained knowledge of fundamental and high-level concepts, is a subject matter expert, is proficient in an expertise course covering the professional code of conduct and follows recognized standards of practice.

Professor Tzenios communicates his ideas with spontaneous ease and shows academic commitment and research aptitude, which give us enough ground to believe that he has the potential to render yeomanly services in the academic field. This gives us enough ground to believe his knowledge will benefit the upcoming research scholars.

Almost all the leading indexing organizations have indexed Global Journals Organisation journals. It publishes journals in forty disciplines bringing out around three hundred research articles per month read by about two hundred thousand readers in different parts of the world. Research contribution comes from renowned researchers and scientists from universities of one hundred fifty-seven countries. The organization has to its credit the publication of more than eighteen thousand research works.

Dr. Nikolaos Tzenios the Senior Executive Vice-President of the World Academy of Medical (https://www.linkedin.com/in/nicolastzenios) is a member of the Scientific board of the European Medical Association, a Fellow of The Royal Society for Public Health (UK), a Fellow of The Royal Society of Medicine (UK), a Fellow of the World Academy of Medical Sciences, a Fellow of the American Academy of Anti-Aging Medicine.

Dr. Tzenios is also a Member of the American Academy of Regenerative Medicine, a Member The European Academy of Allergy and Clinical Immunology, a Member American Academy of Allergy, Asthma & Immunology (AAAAI), and Member the American Federation for Medical Research, a Member of the Royal Society of Biology (U.K.) and an ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences.

Media ContactCompany Name: Release NewsContact Person: Andrew BraithwaiteEmail: Send EmailPhone: +44 (0) 161 818 6487Country: United StatesWebsite: https://release-news.com/

Original post:
Professor Dr.Tzenios was inducted into the hall of Fame of the Medical Research Council (FMRC) USA by honoring him with a distinguished FMRC...

Immunology

Senior Lecturer, Bacteriology job with UNIVERSITY OF MELBOURNE | 304525 – Times Higher Education

Location:ParkvilleRole type:Full time; ContinuingFaculty:Faculty of Medicine, Dentistry and Health SciencesDepartment/School:Department of Microbiology and ImmunologySalary:Level C $135,032 $155,698 p.a. plus 17% super

The University of Melbourne would like to acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated, the Wurundjeri and Boon Wurrung Peoples, the Yorta Yorta Nation, and the Dja Dja Wurrung People. We acknowledge that the land on which we meet and learn was the place of age-old ceremonies, celebration, initiation, and renewal, and that the local Aboriginal Peoples have had and continue to have a unique role in the life of these lands.

About The Department of Microbiology & Immunology

TheDepartment of Microbiology & Immunologyis one of three departments within the School of Biomedical Sciences in the Faculty of Medicine, Dentistry, and Health Sciences and is also an integral component of the Peter Doherty Institute for Infection and Immunity (http://www.doherty.unimelb.edu.au).

It accommodates nearly 40 research laboratories which span areas including bacteriology, virology, immunology, pathology, and cancer biology, a team of dedicated teaching specialists, and the Microbiology Diagnostic Unit, a public health microbiology diagnostic laboratory.

About the Role

As part of the departments strategic plan to build and strengthen its bacteriology discipline, we are seeking to fill two teaching and research positions; in addition to the Senior Lecturer, applications for Associate Professor / Professor in Bacteriology will be opening soon.

Along with an independent research program, you will make a major contribution to teaching in the field of microbiology as well as the associated curriculum, policy development, and administrative tasks. This will include responsibilities in specific undergraduate subjects including course coordination and the planning, implementation, and delivery of teaching activities as well as assessment approaches.

Further responsibilities include:

Located within the Parkville precinct, you will have access to world-leading infrastructure at the Bio21 Institute, as well as the superior equipment and resources of the Peter Doherty Institute.

About You

This role is well positioned to form productive linkages with the numerous research and health centres that are collocated within the precinct and as such, you will utilise your strong interpersonal skills to collaborate within the Department, the Doherty Institute, and the wider University precinct.

You are a natural leader and have an established track record in bacteriology, with clear potential to build a prominent and productive research program that complements the Department and Institute strengths in infection and immunity. Applicants with research programs that use innovative approaches to study host-pathogen interactions are particularly encouraged to apply.

You will also have:

To ensure the University continues to provide a safe environment for everyone, this position requires the incumbent to hold a current and valid Working with Children Check.

About the University

The University of Melbourne is consistently ranked amongst the leading universities in the world. We are proud of our people, our commitment to research and teaching excellence, and our global engagement.

Benefits of Working with Us

In addition to having the opportunity to grow and be challenged, and to be part of a vibrant campus life, our people enjoy a range of rewarding benefits:

To find out more, visithttps://about.unimelb.edu.au/careers/staff-benefits.

Be Yourself

We value the unique backgrounds, experiences and contributions that each person brings to our community and encourage and celebrate diversity. First Nations people, those identifying as LGBTQIA+, females, people of all ages, with disabilities and culturally and linguistically diverse people are encouraged to apply. Our aim is to create a workforce that reflects the community in which we live.

Join Us!

If you feel this role is right for you, please submit your application including a brief cover letter, your resume and your responses against the selection criteria^ (found in the Position Description) for the role.

^For information to help you with compiling short statements to answer the selection criteria and competencies, please go tohttp://about.unimelb.edu.au/careers/selection-criteria

We are dedicated to ensuring barrier free and inclusive practices to recruit the most talented candidates. If you require any reasonable adjustments with the recruitment process, please contact us athr-talent@unimelb.edu.au.

Position Description:0039842_Senior Lecturer_Bacteriology_PD.pdf

Applications close:21 SEPT 2022 11:55 PMAUS Eastern Standard Time

More:
Senior Lecturer, Bacteriology job with UNIVERSITY OF MELBOURNE | 304525 - Times Higher Education

Embryology

Pig Development – Embryology – UNSW Sites

Introduction

Pig (Sus scrofa) developmental model is studied extensively due to the commercial applications of pigs for meat production and for health issues such as obesity, cardiovascular disease, and organ transplantation (xenotransplantation).

Historically, there is an excellent description of the pig reproductive estrous cycle and the cyclic changes that occur within the ovary.[1]

This table allows an automated computer search of the external PubMed database using the listed "Search term" text link.

References listed on the rest of the content page and the associated discussion page (listed under the publication year sub-headings) do include some editorial selection based upon both relevance and availability.

More? References | Discussion Page | Journal Searches | 2019 References | 2020 References

Search term: Pig Embryology | Pig Development

See also the Discussion Page for other references listed by year and References on this current page.

Taxonomy ID: 9823

Genbank common name: pig

Inherited blast name: even-toed ungulates

Rank: species

Genetic code: Translation table 1 (Standard)

Mitochondrial genetic code: Translation table 2 (Vertebrate Mitochondrial)

Other names: wild boar, swine, pigs

Lineage (full): cellular organisms; Eukaryota; Fungi/Metazoa group; Metazoa; Eumetazoa; Bilateria; Coelomata; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata; Teleostomi; Euteleostomi; Sarcopterygii; Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae; Sus

Table data - Otis and Brent (1954)[8]

The images below are from the 1897 Normentafeln zur Entwicklungsgeschichte der Wirbeltiere - Sus scrofa domesticus (Normal Plates of the Development of the Pig Embryo) by Franz Keibel

Diagram showing form and dimensions of the uterus and Fallopian tubes of the sow.[1] Drawn from an average specimen taken from a young mature animal.

Female pig is called a sow.

Events of the average cycle of 21 days in the non-pregnant sow.[1]

Diagram showing relationship between oestrua, ovulation, corpus luteum development, and the progress of the ova in the sow.

Events of the first weeks of pregnancy.[1]

Diagram showing relationship between oestrua, ovulation, corpus luteum development, and the progress of the ova in the sow.

Scanning electron microscope images of the endometrial surface of a Day 13 pregnant sow.[9]

Male pig is called a boar.

Capacitation alters the ultrastructure of the apical head and the acrosome of boar sperm.[6]

Model for capacitation-induced stable docking of the acrosome to the sperm plasma membrane.[6]

The testis of the pig receives its first blood supply when the embryo is 33 mm in length.[10]

The data below is summarised from an excellent study of early neural development in the pig.[11] The same authors have studied neural development in the rabbit.

anterior neuropore

22 somite embryo - anterior neuropore is completely closed. (closure sites for the anterior neuropore in mouse embryo, none of these were detected in the pig embryo)

posterior neuropore

8-20 somite embryos - the width of the posterior neuropore does not change, while the rate of closure gradually increases.

Plates below are from a 1916 thesis on palate development in the pig.[12]

Fig. 2. Ventral view of the roof of the primitive mouth of the 17 mm. embryo.

Fig. 3. Ventral view of the roof of the primitive mouth of the 20 mm. embryo.

Fig.4. Ventral view of the roof of the primitive mouth of the 25 mm. embryo.

Fig. 5. Ventral View of the roof of the primitive mouth of the 27 mm. embryo.

Fig. 6. Ventral view of the roof of the secondary mouth of the 50 mm. embryo.

Fig. 7. Ventral view of the roof of the secondary mouth of the 39 mm. embryo.

Fig. 8. Ventral View of the roof of the secondary mouth of the 70 mm. embryo.

Fig. 10. Cross-section of the head of the 12 mm. embryo posterior fig. 9, showing the union of the processes on one side and the blind sac on the other.

Fig. 11. Cross-section through the head of a 17 mm. embryo showing primitive choanae.

Fig. 12. Cross~section through the anterior region of the head of a 27 mm embryo showing the shorter palatal processes.

Fig. 13. Cross-section through the head of a 27 mm. embryo posterior to fig. 12, to show the processes longer in this middle region.

Fig. 14. Cross-section of the head of the 50 mm. embryo, showing the anterior communication of the nasal and mouth cavities.

Fig. 15. Cross-section through the head of the 30 mm. embryo, posterior to fig. 14, to show the fusion of the processes, the slight indication of the invasion of mesemchyme and the fusion of the processes with the nasal septum.

Fig. 16. Cross-section through the head of the 30 mm. embryo in the posterior region to show the ventral separation.

Fig. 17. Cross-section of the 39 mm. embryo cut slightly oblique, showing on one side the respiratory duct cut off,on the other, the connexion with the respiratory cavity.

Miniature Pig Palate Timeline[2]

Arrangement of lymphatic vessels in 40 mm embryo

Lymphatic vessel network in embryo skin. A 18 mm; B 20 mm; C 30 mm; D 40 mm

Transverse section spinal cord 20 cm embryo

Wall of uterus and chorion

Transverse section of umbilical cord of a pig embryo six inches in length

Recent References

Buddington RK, Sangild PT, Hance B, Huang EY & Black DD. (2012). Prenatal gastrointestinal development in the pig and responses after preterm birth. J. Anim. Sci. , 90 Suppl 4, 290-8. PMID: 23365359 DOI.

Somfai T, Kikuchi K & Nagai T. (2012). Factors affecting cryopreservation of porcine oocytes. J. Reprod. Dev. , 58, 17-24. PMID: 22450280

Ostrup E, Hyttel P & Ostrup O. (2011). Embryo-maternal communication: signalling before and during placentation in cattle and pig. Reprod. Fertil. Dev. , 23, 964-75. PMID: 22127002 DOI.

Waclawik A. (2011). Novel insights into the mechanisms of pregnancy establishment: regulation of prostaglandin synthesis and signaling in the pig. Reproduction , 142, 389-99. PMID: 21677026 DOI.

Robison OW. (1976). Growth patterns in swine. J. Anim. Sci. , 42, 1024-35. PMID: 770410

Book SA & Bustad LK. (1974). The fetal and neonatal pig in biomedical research. J. Anim. Sci. , 38, 997-1002. PMID: 4596894

Moor RM. (1968). Foetal homeostasis: conceptus-ovary endocrine balance. Proc. R. Soc. Med. , 61, 1217-26. PMID: 4973146

Moor RM. (1968). Effect of embryo on corpus luteum function. J. Anim. Sci. , 27 Suppl 1, 97-118. PMID: 4951167

Zhang L, Lin Z, Bi Y, Zheng X, Xiao H & Hua Z. (2018). CO2 concentration affects in vitro pig embryo developmental capacity. Pol J Vet Sci , 21, 609-614. PMID: 30468346 DOI.

Liu J, Zhu Y, Luo GZ, Wang X, Yue Y, Wang X, Zong X, Chen K, Yin H, Fu Y, Han D, Wang Y, Chen D & He C. (2016). Abundant DNA 6mA methylation during early embryogenesis of zebrafish and pig. Nat Commun , 7, 13052. PMID: 27713410 DOI.

Hassoun R, Schwartz P, Rath D, Viebahn C & Mnner J. (2010). Germ layer differentiation during early hindgut and cloaca formation in rabbit and pig embryos. J. Anat. , 217, 665-78. PMID: 20874819 DOI.

Search Pubmed: pig development | pig embryo | Sus scrofa development

External Links Notice - The dynamic nature of the internet may mean that some of these listed links may no longer function. If the link no longer works search the web with the link text or name. Links to any external commercial sites are provided for information purposes only and should never be considered an endorsement. UNSW Embryology is provided as an educational resource with no clinical information or commercial affiliation.

Cite this page: Hill, M.A. (2022, August 16) Embryology Pig Development. Retrieved from https://embryology.med.unsw.edu.au/embryology/index.php/Pig_Development

See the rest here:
Pig Development - Embryology - UNSW Sites

Embryology

Master of Clinical Embryology – Study at Monash University

The Intensive Master of Clinical Embryology is internationally renowned as a training program for all assisted reproductive technologies (ART), producing high calibre embryologists. On completion of this course, you will have developed the specialised knowledge and practical skills needed to work in, and manage, human ART clinics.

The course is offered both on-campus (one year full time) and off-campus (restricted entry, full or part-time) to domestic and international students.

Your studies will include the foundations of mammalian embryology, detailed assessment of all infertility treatment strategies and the theoretical basis behind embryo production, embryo selection and cryopreservation, with a focus on all current and future technologies associated with ART. You will also study units dedicated to Total Quality Management, Preimplantation Diagnosis and Ethics.

Throughout the course you will acquire all the practical skills required of andrologists and embryologists, from sperm and embryo handling and assessment, to in vitro fertilisation techniques and cryopreservation techniques, including vitrification of gametes and embryos. You will finish the year learning ICSI and biopsy procedures.

While learning the practical skills, you are also given opportunities to visit ART clinics and attend ART industry conferences within Australia and internationally. You will engage in research projects that are designed to enhance your practical and research skills, while assessments throughout the year are designed to measure your competency in theoretical, practical and research disciplines.

More here:
Master of Clinical Embryology - Study at Monash University

Embryology

Letter: The inconvenient science of embryology – INFORUM

In a recent letter, " How to keep abortion legal ," the writer stated that fetuses in their first 12 weeks ... have zero brain function and do not respond to stimuli of any kind. In another letter, " The war on women is escalating ," the writer refers to the unborn human life as a blob of protoplasm. Whether these statements of blatant misinformation were intentional, or simply from an extreme lack of knowledge, they certainly need to be corrected.

The scientific facts are that at just 3 weeks from conception (approximately 5 weeks gestational age) the first signs of brain development are evident, and by 4 weeks from fertilization the basic structure for the entire central nervous system has formed. At 8 weeks the babys brain is growing rapidly, producing almost 250,000 new neurons each minute. At this point the embryo can respond to touch by reflex and the brain can make the muscles move on purpose.

By 9 weeks from fertilization the baby has all of the major organ systems and is a distinctly recognizable human being now known as a fetus, a Latin word for young one. The heart was the first organ to function by the third week (18-21 days) from fertilization. By the fourth week it can be observed on an ultrasound scan beating about 80 times a minute. In addition, by this time the eyes are developing, and the arm and leg buds are visible. Also, keep in mind that from the very moment of conception all the genetic information for every detail of this newly created and unique life is present.

All of the above facts refer to the developing human being in its first 12 weeks from conception, the time when most abortions are done. These scientific facts of embryology come from a number of sources including embryology textbooks, National Geographic, the Mayo Foundation for Medical Education and Research, and other sources too numerous to mention in the space allowed here.

While we are always told to follow the science, apparently when it comes to abortion we are instead expected to disregard this inconvenient science of embryology completely. In a recent documentary movie The Matter Of Life, Dr. Anthony Levatino, an OB GYN specialist who had performed over 1,200 abortions, stated that one day during a routine abortion his clamp pulled out an arm and a leg and it finally hit him that this was someones son or daughter. He got sick and never did another abortion again. He also stated that It doesnt matter what size the unborn baby is - its the same human life! Dr. Levatino is right. Human life of any age is human life and should be protected as such. And, as these little ones cannot protect themselves, it is up to us to do so.

Dr. Bernard Nathanson, another former abortionist, who became pro-life after watching the unborn baby on an ultrasound during an abortion concluded the documentary by stating: Lets all, for humanity sake, stop the killing! Yes indeed, let us!

Ken Koehler lives in West Fargo.

This letter does not necessarily reflect the opinion of The Forum's editorial board nor Forum ownership.

See the article here:
Letter: The inconvenient science of embryology - INFORUM

Embryology

Letters to the Editor August 13, 2022 | The Citizen – Ortonville Citizen

What is pro life?Shouldnt government deciding to end abortions understand embryology? Long term consequences? Responsibility forbothparents?Most seeking abortion for reasons other than medical issues do so in the first trimester, when the fetus is not viable and there is no brain. It takes 28 weeks until the embryo senses touch , hearing and smell. Do those who are against abortion consider taking a brain dead person off of life support murder?The person half (or more) responsible for the pregnancy is never mentioned in the anti-abortion laws. If we care about the unborn child arent both parents responsible? Why is it not mandatory we all provide our DNA to be registered in an international data bank, so that both mother and father pay their share in the cost of pregnancy (health care, loss of wages etc) and in the upbringing of the child?If those against abortion care about life, could we then also use such registry to harvest an organ for a child that needs one , where we can live without one ?Should we make it mandatory to adopt an unwanted child before we create our own?If we force fetuses being diagnosed with chromosomal or other abnormalities to be born, should we not first have the resources to take care of those children after being born ? And after their parents are no longer there to help them through life? All the parents of such children I know are struggling as this country is not willing to take care of that issue.If you consider life to end with the last breath, would then life start at first breath?Anita BakkerOrtonville

The rest is here:
Letters to the Editor August 13, 2022 | The Citizen - Ortonville Citizen